



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 25-11-2009

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 06-11-2009 TO BE PUBLISHED 26-11-2009 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 99215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

02-11-2009

976/2009	SECRET	“SECRET”
977/2009	SECRET	“SECRET”
978/2009	SECRET	“SECRET”
979/2009	SECRET	“SECRET”
980/2009	Bayer Cropscience AG, Germany. (Priority 05-11-2008 Europe)	“Novel halogen-substituted compounds”
981/2009	N.v. Organon, Netherland (Priority 04-11-2008 Europe)	“(Pyrrolidin-2-yl)phenyl derivatives”
982/2009	Portola Pharmaceuticals, Inc., USA (Priority 05-11-2008 USA)	“Melanocortin receptor agonists”

03-11-2009

983/2009	Wyeth, USA (Priority 05-11-2008 USA)	“Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease”
984/2009	Voestalpine tubulars GmbH & Co., KG, Austria (Priority 20-11-2008 Austria)	“Method and device for the production of steel pipes with particular characteristics”
985/2009	Smithkline Beecham Corporation, USA (Priority 21-04-2006 USA) Divisional	“Pharmaceutically acceptable salt of a substituted piperidinyI-sulfonyl compound”
986/2009	Eli Lilly and Company, USA (Priority 17-12-2008 USA)	“Compounds useful for inhibiting chki”

987/2009	Oerlikon Textile Components GmbH, Germany (Priority 06-11-2008 Germany)	“Top roller carrying and weighting arm for a drafting arrangement”
<u>04-11-2009</u>		
988/2009	Merck & Co., Inc., USA (Priority 13-11-2008 USA)	“Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes”
989/2009	Arena Pharmaceuticals, Inc., USA (Priority 17-10-2006 USA) Divisional	“Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto”
990/2009	Dr. Muhammad Iqbal . Dr, Asma Saeed. PCSIR, Lahore, Pakistan	“A process for the production of biocation exchanger for the removal of toxic metals from wastewaters”
991/2009	Theravance, Inc., USA (Priority 14-11-2008 USA)	“Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound”
992/2009	Amira Pharmaceutical Inc., USA (Priority 6-11-2008 USA)	“Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors”
<u>06-11-2009</u>		
993/2009	H. Lundbeck A/S, Denmark (Priority 07-11-2008 USA)	“Biologically active amides”
994/2009	Sun same Enterprises co., Ltd., Taiwan, R.O.C.	“Handheld stamp assembly”
995/2009	Grt, Inc., USA (Priority 01-07-2009 USA)	“Continuous process for converting natural gas to liquid hydrocarbons”
996/2009	Pfizer Limited, Great Britain (Priority 10-11-2008 USA)	“Pyrrolidines”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

484/2002	F. Hoffmann-La Roche AG, Switzerland	“A pharmaceutical composition comprising orlistat” A61K 9/00
----------	---	---

140324

The present invention relates to a pharmaceutical composition comprising a lipase inhibitor, preferably orlistat, having a melting point $Z 37^{\circ}\text{C}$, a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di, tri-or tetra-ester, and optionally one or more pharmaceutically acceptable excipients.

606/2003	Bayer Pharmaceuticals Corporation, USA	“Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist” C12N 15/12
----------	---	---

140325

This invention provides novel peptide that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptide are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptide of this invention are also stable in formulation and have long half-lives. The peptide of the present invention provide a new therapy for patients with decreased

endogenous insulin secretion. in particular type2 diabetics. In particular the invention is a polypeptide selected from a specific group of VPAC2-related polypeptides, of functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal.

1220/2006 Dr. Bina S. Siddiqui,
Dr. S. Naeem-ul-Hasan
Naqvi,
Dr. Syed Tariq Ali,
Dr. Shaheen Faizi,
International Center for
Chemical Sciences,
University of Karachi

“A process for the preparation of pesticidal composition biosal from the dried neem seeds (KERNEL)”

140326

The invention relates to a new process for the preparation of new agricultural pesticidal composition BIOSAL by extracting neem seeds (kernel) with a co-solvent mixture of a nonpolar, aliphatic hydrocarbon and a polar alcohol solvent in a ratio of 1: 2 by recycling the solvent mixture at 60-80°C three times through the seeds to obtain a viscous extract and adding suitable carrier and inert material to make the composition suitable for dilution with water for spraying to control agricultural pests.

816/2008 Novartis AG.,
Switzerland

“An oral solution comprising telbivudine”

A61K 9/08, A61K 31/513

140327

A pharmaceutical solution suitable for oral administration comprising β -L-thymidine/2'-deoxy-L-thymidine (telbivudine), a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents, a preservative system, and a buffer system suitable to allow both drug stability and preservation.

900/2008 Honda Motor Co., Ltd.,
Japan

“Automotive rear vehicle body structure”

B62D 25/20

140328

Provided is an automotive rear vehicle body structure which increases the amount of energy that can be absorbed, improves the safety of the vehicle occupant and protects a fuel tank in a reliable manner at the time of a rear end collision while allowing a spare tire to be placed within a cabin. In an automotive rear vehicle body structure having a H-type torsion beam wheel suspension system (12) pivotally supported by side sill extensions (2a, 3a) on either side of the vehicle body, the wheel suspension system including a pair of trailing arms (13, 14) and a torsion beam (15) connecting intermediate parts of the trailing arms with each other, a pair of rear side frames (6, 7) extend rearwardly from side sills (2,3), and a spare tire pan (10) is defined by downwardly bulging a part of a rear floor panel (11) located between the rear side frames (6, 7). A pair of rear center frames (21, 22) extending in a fore-and-aft direction are located behind the torsion beam (15) and attached to the lower surface of a bottom wall (10a) of the spare tire pan (10).

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 99215488